Alzheimer's Disease and Dementia
Our work in Alzheimer's Disease and Dementia
-
Leveraging Alzheimer’s Disease Clinical Trial Outcomes in Health Economics Research
Join the Schaeffer Center for an academic seminar on the implications of clinical trial design on Alzheimer’s disease modeling.
-
Impact of Non-Binding FDA Guidances On Primary Endpoint Selection in Alzheimer’s Disease Trials
Researchers examine the impact of two guidance documents for Alzheimer’s disease (AD) trials. The first guidance in 2013 encouraged the use of cognitive/functional endpoints, while the second in 2018 modified such recommendation.
-
Barriers to Seeking Care for Memory Problems: A Vignette Study
Abstract Introduction: This study compares how older adults judge the need for follow-up care for memory-related problems when they are responding about themselves versus someone of the same age. Methods: Adults ages 65 and over in the Understanding America Study, a nationally representative internet panel, were invited to participate in a short survey with three […]
Categorized in -
The Rising Burden of Alzheimer’s Disease Mortality in Rural America
Since the 1990s, there has been a striking urban-rural divergence in life expectancy within the United States, with metropolitan areas achieving strong life expectancy increases and nonmetropolitan areas experiencing stagnation or actual declines in life expectancy.
-
Global Projections of Dementia: United States, Ireland, Japan and Mexico
On March 9, join a webinar on projections of population-level cognitive impairment and dementia in the US, Ireland, Japan, and Mexico. The panel will also discuss how simulation modeling can be used for projecting costs and health outcomes of new therapeutics for AD/ADRD.
-
Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
Schaeffer Center researchers have found older Americans know little about aducanumab, despite the fact that an overwhelming majority of survey respondents said they were worried about Alzheimer’s disease.
-
Study Finds Older Americans Are Largely Unaware of a New Alzheimer’s Drug
Among older Americans surveyed in the weeks after FDA approval of aducanumab, few could correctly answer true or false questions about the first new Alzheimer’s drug in decades.
-
New USC Study Finds People of Color Live More Years with Dementia Diagnosis Than Non-Hispanic Whites
These findings further reinforce the need for targeted support and resources for families and patients living with Alzheimer’s and other dementias.
-
Aduhelm Decision Shows Medicare is Making a Mistake in the Fight Against Alzheimer’s
The medical need is too great that the FDA should not limit targeted therapies and diagnostics.
Categorized in -
Racial and Ethnic Differences in Risk and Protective Factors of Dementia and CIND in the United States
Recent population-based studies have shown declines in dementia prevalence in high-income countries, suggesting that improved population cardiovascular health and rising levels of education in the past 25 year were associated with reduction of dementia risks.